智通财经APP讯，康泰生物(300601.SZ)发布公告，公司全资子公司北京民海生物科技有限公司研发的吸附无细胞百白破(组分)联合疫苗已完成Ⅲ期临床试验准备工作，开启Ⅲ期临床试验，并于今日成功完成首例受试者入组。
据悉，吸附无细胞百白破(组分)联合疫苗适用于2月龄及以上的婴幼儿，接种本疫苗后，可使机体产生免疫应答，用于预防百日咳、白喉、破伤风。该疫苗中的百日咳抗原可精确定量，保证有效成分的批间一致性。
经查询国家药品监督管理局网站，目前国内厂家暂无吸附无细胞百白破(组分)联合疫苗的产品获批上市。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.